Katz S M, Ozaki C F, Monsour H P, Fontenot D, Baumann L, Thomas M, Weldon M, Hoef J, Wood R P
University of Texas Medical School at Houston 77030.
Transplant Proc. 1994 Feb;26(1):145-6.
Living-related liver transplantation is becoming more commonplace worldwide in the treatment of end-stage liver disease in the pediatric age group. Our LRD experience has resulted in patient and graft survival rates comparable to our cadaveric donor recipients. The incidence and severity of acute rejection episodes were similar. This differs from the clear immunologic advantage of living-related donation in kidney transplantation. It may, however, reflect the relatively small numbers in our LRD group. Overall, however, the technical complications are manageable with early intervention, yielding acceptable results.
在全球范围内,亲属活体肝移植在治疗小儿终末期肝病方面正变得越来越普遍。我们在亲属活体供肝移植方面的经验表明,患者和移植物的存活率与尸体供肝受者相当。急性排斥反应的发生率和严重程度相似。这与亲属活体肾移植中明显的免疫优势不同。然而,这可能反映出我们亲属活体供肝移植组的病例数相对较少。不过总体而言,技术并发症通过早期干预是可控的,能产生可接受的结果。